Gleamer Expands Medical AI Horizon with Acquisitions of Pixyl and Caerus Med | Free ai tools online | Free ai image generator from text | Best dall e free alternative reddit | Turtles AI

Gleamer, a leader in AI-based medical imaging, has acquired Pixyl and Caerus Medical, expanding its offering to include MRI applications. This move strengthens its position in the radiology AI market.

Key Points:

• Strategic Expansion: Gleamer integrates AI solutions for brain and lumbar MRI.
• Comprehensive Portfolio: Now covering X-ray, mammography, CT and MRI.
• Continuous Innovation: Focus on diagnostic efficiency and patient care.
• Global Presence: Over 100 employees in seven countries.

Paris-based Gleamer, a specialist in AI solutions for medical imaging, announced the acquisition of Pixyl and Caerus Medical, both focused on advanced applications for magnetic resonance imaging (MRI). Founded in 2017, Gleamer has developed a suite of AI solutions that help radiologists and physicians improve diagnostic confidence and reduce exam reading times. These solutions are recognized worldwide, with over 30 publications in peer-reviewed journals and a presence in more than 2,000 institutions in 45 countries.

Pixyl, born as a spin-off of the French laboratories Inria and Inserm in 2015, is known for Pixyl.Neuro, a technology that uses AI to detect abnormalities in brain MRI images, facilitating the early diagnosis of neuroinflammatory and neurodegenerative disorders, such as Alzheimer’s. This software has obtained both FDA approval and CE marking as a Class IIa medical device, ensuring high standards of safety and efficacy.

Caerus Medical, founded in 2020 in Paris, focuses on AI analysis of musculoskeletal MRI images. Its main product, LumbAI, is designed to detect lumbar pathologies in MRI scans, supporting radiologists and specialists in the diagnosis of back pain. The goal is to improve workflow efficiency and diagnostic confidence by simplifying the reporting process.

These strategic acquisitions allow Gleamer to expand its offerings to include cutting-edge MRI applications and strengthen its leadership in AI for medical imaging. With a global workforce of over 100 employees across seven countries, Gleamer continues to invest in research and development to accelerate innovation and ensure rapid delivery of next-generation imaging solutions, meeting the evolving needs of modern radiology.

Previously, in 2023, Gleamer raised €27 million in a Series B funding round, led by Supernova Invest and Heal Capital, with participation from several European radiologists. This investment was intended to expand the company’s solutions portfolio and strengthen its teams in Europe and the United States.

With the integration of Pixyl and Caerus Medical, Gleamer is positioned as the only AI provider with a suite of proprietary solutions covering all major imaging modalities: X-ray, mammography, CT and MRI. This strategic move further consolidates its leadership in the radiology AI market, offering healthcare professionals advanced tools to optimize efficiency, improve diagnostic accuracy and accelerate patient care.

With a presence in over 2,000 institutions and coverage in 45 countries, Gleamer’s solutions are widely recognized in the medical imaging industry. The company remains committed to providing innovative tools that support radiologists in their diagnoses, helping to improve the quality of healthcare globally.

Gleamer’s acquisition of Pixyl and Caerus Medical represents an important step in the evolution of AI-based medical imaging, expanding its diagnostic capabilities and strengthening the company’s position as a leader in the industry.